Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy
International Journal of Cancer · 2026
DOI: 10.1002/ijc.70342 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, 2026. Verfasst von Yuna Lee und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Ascites, Stomach Neoplasms, Nivolumab, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Although malignant ascites is associated with poor outcomes in gastric cancer (GC), its clinical value in first‐line immune checkpoint inhibitor (ICI)‐based chemotherapy remains unclear. This single‐center study aimed to evaluate the impact of malignant ascites in patients with advanced GC treated with first‐line nivolumab plus chemotherapy ( n = 339) or chemotherapy alone ( n = 422). Peritoneal involvement and malignant ascites grade were assessed using computed tomography imaging. Patients were classified into no peritoneal metastases (PM), PM without ascites, and PM with ascites groups. In the nivolumab plus chemotherapy group, patients with PM and ascites exhibited significantly worse survival (median PFS: 5.1 months; OS: 11.6 months) than those with no PM (median PFS: 10.2 months; OS: 22.0 months) or PM without ascites (median PFS: 10.8 months; OS: 19.7 months) ( p < 0.001). While nivolumab plus chemotherapy was evidently associated with favorable survival outcomes for patients without malignant ascites compared to chemotherapy (PFS: p < 0.001; OS: p = 0.01), such survival benefits were not observed in those with PM and ascites (PFS: p = 0.09; OS: p = 0.39). This trend persisted in the PD‐L1 combined positive score ≥5 and deficient mismatch repair subgroups. Our results reveal that malignant ascites is associated with poor survival with nivolumab plus chemotherapy, and limited benefit from adding nivolumab to chemotherapy in patients with GC. We suggest that malignant ascites may be considered a stratification factor in future clinical trials of ICI‐based treatments for GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Yuna Lee, Min-Hee Ryu
Zitieren
APA
Lee, Y., Kim, H. D., Lee, H., Hyung, J., Moon, M., Ma, J., & Ryu, M. H. (2026). Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy. International Journal of Cancer. https://doi.org/10.1002/ijc.70342
Vancouver
Lee Y, Kim HD, Lee H, Hyung J, Moon M, Ma J, et al. Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy. International Journal of Cancer. 2026. doi:10.1002/ijc.70342
BibTeX
@article{Lee2026,
author = {Lee, Yuna and Kim, Hyung-Don and Lee, Hyungeun and Hyung, Jaewon and Moon, Meesun and Ma, Jungeun and Ryu, Min-Hee},
title = {Association between the presence of malignant ascites and survival outcomes in gastric cancer patients treated with nivolumab plus chemotherapy},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70342}
}
EUVIMED